Raiza Amiling1,2, Elissa Meites1, Troy D Querec3, Laura Stone4, Vidisha Singh1, Elizabeth R Unger3, Craig S Derkay4,5, Lauri E Markowitz1. 1. Division of Viral Diseases, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, USA. 2. Synergy America, Inc., Duluth, Georgia, USA. 3. Division of High-Consequence Pathogens and Pathology, National Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, USA. 4. Department of Otolaryngology-Head and Neck Surgery, Eastern Virginia Medical School, Norfolk, Virginia, USA. 5. Pediatric Otolaryngology, Children's Hospital of the King's Daughters, Norfolk, Virginia, USA.
Abstract
BACKGROUND: Juvenile-onset recurrent respiratory papillomatosis (JORRP) is a rare disease characterized by the growth of papillomas in the respiratory tract. In the United States, JORRP is not a nationally notifiable condition and current data are limited. METHODS: Children with JORRP aged <18 years were enrolled from 26 pediatric otolaryngology centers in 23 US states from January 2015 through August 2020. Demographic, birth information, and maternal vaccination history were collected from a parent/guardian. Clinical history was abstracted from medical records. Papilloma biopsies were tested for 28 human papillomavirus (HPV) types. Mothers who delivered in 2006 or later were considered age-eligible for HPV vaccination if aged ≤26 years in 2006. We described characteristics of enrolled children and their birth mothers and analyzed disease severity by diagnosis age and HPV type using multiple logistic regression. RESULTS: Among 215 children with JORRP, 88.8% were delivered vaginally; 64.2% were firstborn. Among 190 mothers, the median delivery age was 22 years. Among 114 (60.0%) age-eligible for HPV vaccination, 16 (14.0%) were vaccinated, 1 (0.9%) before delivery. Among 162 specimens tested, 157 (96.9%) had detectable HPV; all 157 had a vaccine-preventable type. Disease severity was associated with younger diagnosis age and HPV 11; adjusted analyses found only younger diagnosis age significant (adjusted odds ratio: 6.1; 95% confidence interval: 2.9, 12.8). CONCLUSIONS: Children with JORRP were commonly firstborn and delivered vaginally to young mothers; most of the mothers reported no HPV vaccination before delivery. Vaccine-preventable HPV was identified in all specimens with detectable HPV. Increasing preexposure HPV vaccination could substantially reduce or eliminate JORRP in the United States. Published by Oxford University Press on behalf of The Journal of the Pediatric Infectious Diseases Society 2021.
BACKGROUND: Juvenile-onset recurrent respiratory papillomatosis (JORRP) is a rare disease characterized by the growth of papillomas in the respiratory tract. In the United States, JORRP is not a nationally notifiable condition and current data are limited. METHODS: Children with JORRP aged <18 years were enrolled from 26 pediatric otolaryngology centers in 23 US states from January 2015 through August 2020. Demographic, birth information, and maternal vaccination history were collected from a parent/guardian. Clinical history was abstracted from medical records. Papilloma biopsies were tested for 28 human papillomavirus (HPV) types. Mothers who delivered in 2006 or later were considered age-eligible for HPV vaccination if aged ≤26 years in 2006. We described characteristics of enrolled children and their birth mothers and analyzed disease severity by diagnosis age and HPV type using multiple logistic regression. RESULTS: Among 215 children with JORRP, 88.8% were delivered vaginally; 64.2% were firstborn. Among 190 mothers, the median delivery age was 22 years. Among 114 (60.0%) age-eligible for HPV vaccination, 16 (14.0%) were vaccinated, 1 (0.9%) before delivery. Among 162 specimens tested, 157 (96.9%) had detectable HPV; all 157 had a vaccine-preventable type. Disease severity was associated with younger diagnosis age and HPV 11; adjusted analyses found only younger diagnosis age significant (adjusted odds ratio: 6.1; 95% confidence interval: 2.9, 12.8). CONCLUSIONS: Children with JORRP were commonly firstborn and delivered vaginally to young mothers; most of the mothers reported no HPV vaccination before delivery. Vaccine-preventable HPV was identified in all specimens with detectable HPV. Increasing preexposure HPV vaccination could substantially reduce or eliminate JORRP in the United States. Published by Oxford University Press on behalf of The Journal of the Pediatric Infectious Diseases Society 2021.
Entities:
Keywords:
child; human papillomavirus 11; human papillomavirus 6; laryngeal neoplasms; recurrent respiratory papillomatosis
Authors: L R Armstrong; E J Preston; M Reichert; D L Phillips; R Nisenbaum; N W Todd; I N Jacobs; A F Inglis; S C Manning; W C Reeves Journal: Clin Infect Dis Date: 2000-07-11 Impact factor: 9.079
Authors: Elizabeth M Maloney; Elizabeth R Unger; Ruth Ann Tucker; David Swan; Kevin Karem; N Wendell Todd; William C Reeves Journal: Arch Otolaryngol Head Neck Surg Date: 2006-07
Authors: William C Reeves; Snehal S Ruparelia; Katherine I Swanson; Craig S Derkay; Avron Marcus; Elizabeth R Unger Journal: Arch Otolaryngol Head Neck Surg Date: 2003-09
Authors: Michael J Silverberg; Poul Thorsen; Henning Lindeberg; Linda Ahdieh-Grant; Keerti V Shah Journal: Arch Otolaryngol Head Neck Surg Date: 2004-06
Authors: Elissa Meites; Laura Stone; Raiza Amiling; Vidisha Singh; Elizabeth R Unger; Craig S Derkay; Lauri E Markowitz Journal: Clin Infect Dis Date: 2021-09-07 Impact factor: 20.999
Authors: Cornelia Peterson; Rupin N Parikh; Meleha T Ahmad; Ashley A Campbell; Yassine Daoud; Nicholas Mahoney; Sepideh Siadati; Charles G Eberhart Journal: Int J Mol Sci Date: 2022-06-29 Impact factor: 6.208
Authors: Renee E King; Andrea Bilger; Josef Rademacher; Ella T Ward-Shaw; Rong Hu; Paul F Lambert; Susan L Thibeault Journal: Viruses Date: 2022-05-08 Impact factor: 5.818
Authors: Elissa Meites; Laura Stone; Raiza Amiling; Vidisha Singh; Elizabeth R Unger; Craig S Derkay; Lauri E Markowitz Journal: Clin Infect Dis Date: 2021-09-07 Impact factor: 20.999